Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer-Reference-Cited by-同舟云学术

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

Published:2019-10-21 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Cameron Laird B¹,Hitchen Nadia¹,Jordan Vanessa²,Manser Renée³,Solomon Benjamin J⁴

Affiliation:

1. Auckland District Health Board; 2 Park Road Grafton Auckland New Zealand 1023

2. University of Auckland; Department of Obstetrics and Gynaecology; Private Bag 92019 Auckland New Zealand 1003

3. and Department of Respiratory Medicine, Royal Melbourne Hospital; Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St Andrew's Place, East Melbourne 3002, Victoria; 305 Grattan Street Melbourne Australia 3000

4. Peter MacCallum Cancer Centre; Department of Medical Oncology; 305 Grattan Street Melbourne Australia 3000

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013453/epdf/full

Reference49 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

2. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer;Barrows;Lung Cancer (Auckl),2019

3. Cameron L Solomon B New treatment options for ALK-rearranged non-small cell lung cancer Current Treatment Options in Oncolology 2015 49

4. Treating ALK-positive lung cancer - early successes and future challenges;Camidge;Nature Reviews Clinical Oncology,2012

5. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program;Cetin;Clinical Epidemiology,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations;Frontiers in Molecular Biosciences;2024-01-11

2. P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells;Cancers;2022-05-09